Kurt Lesh
Family Medicine · Colorado Spgs, CONPI 1780629824
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,033 of the $7,035 with a category attached, or 71.5%. 33 manufacturers reported payments, led by AbbVie at 34.3% of the total. Reporting peaked in 2019 at $5,004 and has fallen 84.7% since, to $765 in 2021. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$944
- Amgen$574
- Boehringer Ingelheim$447
- Lilly USA, LLC$249
- Eisai Inc.$225
- plus $2K from 27 others
Across 245 payments — averaging $1864.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$130K
- Merck$106K
- AbbVie$100K
- Eisai Inc.$94K
- Regeneron$10K
- Pfizer$9K
- plus $9K from 3 others
What the payments were for
- Travel & lodging$1,89727%
- Food & beverage$5,03372%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $2,410 |
| AstraZeneca | 29 | $944 |
| Amgen(2 entities) | 20 | $574 |
| Boehringer Ingelheim | 22 | $447 |
| Lilly USA, LLC | 23 | $249 |
| Eisai Inc. | 7 | $225 |
| Astellas Pharma US Inc | 7 | $223 |
| Johnson & Johnson | 12 | $195 |
| Pfizer | 14 | $191 |
| GSK | 5 | $186 |
| Amarin Pharma, Inc. | 10 | $181 |
| Esperion Therapeutics, Inc. | 4 | $179 |
| E.r. Squibb & Sons, L.L.C. | 9 | $152 |
| W. L. Gore & Associates, Inc. | 1 | $148 |
| Merck | 10 | $136 |
| Sanofi-aventis U.S. LLC | 6 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $88 |
| Kowa Pharmaceuticals America, Inc. | 6 | $76 |
| Nevro Corp. | 2 | $54 |
| Genentech USA, Inc. | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Bausch Health US, LLC | 2 | $26 |
| Optinose US, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| Radius Health, Inc. | 1 | $13 |
| Vertiflex, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI AEROSPHERE$249
- EXCLUDER AAA Endoprosthesis$148
- NEXLIZET$125
- NEXLETOL$125
- Dayvigo$125
- ELIQUIS$109
- BEXSERO$109
- EVENITY$109
- Repatha$107
- FARXIGA$103
How this compares
$7,035 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Colorado Spgs
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.